MDGL.NASDAQMadrigal Pharmaceuticals, INC
Form 4: Madrigal Pharmaceuticals CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
William John Sibold, President and CEO and a Director of Madrigal Pharmaceuticals, Inc., sold 11,583 shares of common stock on September 9, 2026.
Summary
- Open-market sale: disposed of 131 Common Stock at $527.88 ($69,152) on September 9, 2026; holds 209,198 after (Direct).
- Open-market sale: disposed of 347 Common Stock at $529.27 ($183,656) on September 9, 2026; holds 208,851 after (Direct).
- Open-market sale: disposed of 522 Common Stock at $530.23 ($276,781) on September 9, 2026; holds 208,329 after (Direct).
- Open-market sale: disposed of 368 Common Stock at $531.99 ($195,772) on September 9, 2026; holds 207,961 after (Direct).
- Open-market sale: disposed of 512 Common Stock at $533.09 ($272,944) on September 9, 2026; holds 207,449 after (Direct).
- Open-market sale: disposed of 396 Common Stock at $534.20 ($211,542) on September 9, 2026; holds 207,053 after (Direct).
- Open-market sale: disposed of 644 Common Stock at $535.27 ($344,715) on September 9, 2026; holds 206,409 after (Direct).
- Open-market sale: disposed of 1,040 Common Stock at $536.11 ($557,557) on September 9, 2026; holds 205,369 after (Direct).
- Open-market sale: disposed of 640 Common Stock at $537.17 ($343,791) on September 9, 2026; holds 204,729 after (Direct).
- Open-market sale: disposed of 520 Common Stock at $538.30 ($279,914) on September 9, 2026; holds 204,209 after (Direct).
- Open-market sale: disposed of 215 Common Stock at $539.03 ($115,891) on September 9, 2026; holds 203,994 after (Direct).
- Open-market sale: disposed of 505 Common Stock at $540.19 ($272,796) on September 9, 2026; holds 203,489 after (Direct).
- Open-market sale: disposed of 362 Common Stock at $541.65 ($196,079) on September 9, 2026; holds 203,127 after (Direct).
- Open-market sale: disposed of 160 Common Stock at $542.55 ($86,808) on September 9, 2026; holds 202,967 after (Direct).
- Open-market sale: disposed of 60 Common Stock at $533.09 ($31,985) on September 11, 2026; holds 202,907 after (Direct).
- Open-market sale: disposed of 106 Common Stock at $534.06 ($56,611) on September 11, 2026; holds 202,801 after (Direct).
- Open-market sale: disposed of 218 Common Stock at $535.94 ($116,836) on September 11, 2026; holds 202,583 after (Direct).
- Open-market sale: disposed of 160 Common Stock at $537.62 ($86,019) on September 11, 2026; holds 202,423 after (Direct).
- Open-market sale: disposed of 687 Common Stock at $540.59 ($371,382) on September 11, 2026; holds 201,736 after (Direct).
- Open-market sale: disposed of 368 Common Stock at $541.64 ($199,324) on September 11, 2026; holds 201,368 after (Direct).
- Open-market sale: disposed of 1,202 Common Stock at $542.60 ($652,209) on September 11, 2026; holds 200,166 after (Direct).
- Open-market sale: disposed of 1,539 Common Stock at $544.02 ($837,253) on September 11, 2026; holds 198,627 after (Direct).
- Open-market sale: disposed of 761 Common Stock at $544.83 ($414,616) on September 11, 2026; holds 197,866 after (Direct).
- Open-market sale: disposed of 120 Common Stock at $546.38 ($65,565) on September 11, 2026; holds 197,746 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,239,198 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
William John Sibold — Director, Officer (President and CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Open-market sale | Common Stock | 131 | $528 | $69.2K | 209,198 |
| 2026-09-09 | Open-market sale | Common Stock | 347 | $529 | $183.7K | 208,851 |
| 2026-09-09 | Open-market sale | Common Stock | 522 | $530 | $276.8K | 208,329 |
| 2026-09-09 | Open-market sale | Common Stock | 368 | $532 | $195.8K | 207,961 |
| 2026-09-09 | Open-market sale | Common Stock | 512 | $533 | $272.9K | 207,449 |
| 2026-09-09 | Open-market sale | Common Stock | 396 | $534 | $211.5K | 207,053 |
| 2026-09-09 | Open-market sale | Common Stock | 644 | $535 | $344.7K | 206,409 |
| 2026-09-09 | Open-market sale | Common Stock | 1,040 | $536 | $557.6K | 205,369 |
| 2026-09-09 | Open-market sale | Common Stock | 640 | $537 | $343.8K | 204,729 |
| 2026-09-09 | Open-market sale | Common Stock | 520 | $538 | $279.9K | 204,209 |
| 2026-09-09 | Open-market sale | Common Stock | 215 | $539 | $115.9K | 203,994 |
| 2026-09-09 | Open-market sale | Common Stock | 505 | $540 | $272.8K | 203,489 |
| 2026-09-09 | Open-market sale | Common Stock | 362 | $542 | $196.1K | 203,127 |
| 2026-09-09 | Open-market sale | Common Stock | 160 | $543 | $86.8K | 202,967 |
| 2026-09-11 | Open-market sale | Common Stock | 60 | $533 | $32.0K | 202,907 |
| 2026-09-11 | Open-market sale | Common Stock | 106 | $534 | $56.6K | 202,801 |
| 2026-09-11 | Open-market sale | Common Stock | 218 | $536 | $116.8K | 202,583 |
| 2026-09-11 | Open-market sale | Common Stock | 160 | $538 | $86.0K | 202,423 |
| 2026-09-11 | Open-market sale | Common Stock | 687 | $541 | $371.4K | 201,736 |
| 2026-09-11 | Open-market sale | Common Stock | 368 | $542 | $199.3K | 201,368 |
| 2026-09-11 | Open-market sale | Common Stock | 1,202 | $543 | $652.2K | 200,166 |
| 2026-09-11 | Open-market sale | Common Stock | 1,539 | $544 | $837.3K | 198,627 |
| 2026-09-11 | Open-market sale | Common Stock | 761 | $545 | $414.6K | 197,866 |
| 2026-09-11 | Open-market sale | Common Stock | 120 | $546 | $65.6K | 197,746 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Open-market sale (131 shares) |
| 2026-09-09 | Open-market sale (347 shares) |
| 2026-09-09 | Open-market sale (522 shares) |
| 2026-09-09 | Open-market sale (368 shares) |
| 2026-09-09 | Open-market sale (512 shares) |
| 2026-09-09 | Open-market sale (396 shares) |
| 2026-09-09 | Open-market sale (644 shares) |
| 2026-09-09 | Open-market sale (1,040 shares) |
| 2026-09-09 | Open-market sale (640 shares) |
| 2026-09-09 | Open-market sale (520 shares) |
| 2026-09-09 | Open-market sale (215 shares) |
| 2026-09-09 | Open-market sale (505 shares) |
| 2026-09-09 | Open-market sale (362 shares) |
| 2026-09-09 | Open-market sale (160 shares) |
| 2026-09-11 | Open-market sale (60 shares) |
| 2026-09-11 | Open-market sale (106 shares) |
| 2026-09-11 | Open-market sale (218 shares) |
| 2026-09-11 | Open-market sale (160 shares) |
| 2026-09-11 | Open-market sale (687 shares) |
| 2026-09-11 | Open-market sale (368 shares) |
| 2026-09-11 | Open-market sale (1,202 shares) |
| 2026-09-11 | Open-market sale (1,539 shares) |
| 2026-09-11 | Open-market sale (761 shares) |
| 2026-09-11 | Open-market sale (120 shares) |
Keywords
insider transaction, Form 4, MDGL, MADRIGAL PHARMACEUTICALS, INC., bearish, William John Sibold
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.